State Street SPDR S&P Biotech ETF vs Utilities Select Sector SPDR Fund — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.19, while Utilities Select Sector SPDR Fund trades at $43.83. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| XBI | XLU | |
|---|---|---|
Sector | Broad Market / Factor | — |
52-Week High | $164.28 | $47.73 |
52-Week Low | $86.92 | $41.31 |
Signals from Pluang's Aura AI — not financial advice
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
XLU, the Utilities Select Sector SPDR Fund, trades at $43.76, up 1.44% today but showing a bearish technical trend with 14 sell signals. The ETF benefits from AI-driven power demand, positioning utilities as growth plays amid easing rates. Recent news highlights unusual call option volume and a dividend scheduled for June 2026, reflecting defensive income appeal.
Outlook is mixed: AI power needs offer growth, but technical weakness and regulatory risks weigh. Investors gain exposure to stable dividends and infrastructure demand, yet face volatility from interest rates and grid capacity constraints. The stock's bearish signals suggest cautious entry points.
Trailing returns across standard periods
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →